Wareysi dhawaan lala yeeshay, Dr. Afsaneh Barzi, oo ah kaaliyaha borofisar ku takhasusay daawaynta kiliinikada ee Jaamacadda Southern California Norris Comprehensive Cancer Centre, ayaa kaaga sheegay daawaynta cusub ee jirta iyo kuwa soo baxaya ee loogu talagalay bukaanada qaba kansarka ganaca ee aan metastatic ahayn.
Gemcitabine waxaa la siiyaa bukaanada qaba kansarka ganaca (pancreatic cancer) oo ah tababar caadi ah oo lagu qiimeeyo jawaabta. Si kastaba ha noqotee, Barzi wuxuu sheegay in jawaabta bukaan-socodka ee gemcitabine ay ahayd mid aad u liidata isla markaana bukaanno badan aysan awoodin inay qalliin galaan. Tijaabada LAPACT waxay baartey daaweynta isku dhafan ee gemcitabine iyo nab-paclitaxel (Abraxane). Tijaabooyinku waxay muujinayaan in 36% bukaanjiifka kansarka ganaca ay ka jawaabaan daaweynta, qiyaastii 15% bukaanjiifka kansarka ganaca ayaa heli kara daaweyn qalliin.
In addition, a meta-analysis of the FOLFIRINOX study of patients with locally advanced pancreatic cancer showed that approximately 28% of pancreatic cancer patients were able to undergo surgery. Barzi explained that as chemotherapy becomes more effective, the likelihood of resection increases. Therefore, the patient’s resection should be evaluated accordingly. Barzi concluded that although most patients may still not be eligible for surgery, it is still worth evaluating patients to find patients who can undergo surgery after neoadjuvant therapy.
